The Milner Therapeutics Institute was established in 2015 with a vision of building close collaborative interactions between academia and industry to help transform groundbreaking science into therapies. The Institute opened on the Cambridge Biomedical Campus in 2019. The outreach programme of the Institute is through the Milner Therapeutics Consortium and the Affiliated Company Partnership scheme. Through the CRUK Cambridge Centre's Onco-Innovation programme, the Milner Institute provides opportunities for researchers to engage with our industry partners and initiate pre-clinical research collaborations.
The Milner Therapeutics Consortium has been active since June 2015 and is based on a research agreement signed by three academic centres in Cambridge and seven pharmaceutical companies: the University of Cambridge, the Sanger Institute and the Babraham Institute; and Astex, AstraZeneca, GlaxoSmithKline, Shionogi, Pfizer, Janssen R&D and Ferring. The agreement is designed to facilitate the speedy exchange of reagents and information for research collaboration with academics across Cambridge. Each industry partner within the Milner Therapeutics Consortium has set aside funds for collaborative projects, which are open to any therapeutic area and are expected to lead to joint publications.